DaVita Inc. $DVA Shares Sold by Allianz Asset Management GmbH

Allianz Asset Management GmbH reduced its position in shares of DaVita Inc. (NYSE:DVA) by 22.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 267,817 shares of the company’s stock after selling 79,066 shares during the period. Allianz Asset Management GmbH owned about 0.38% of DaVita worth $35,585,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the business. NewEdge Advisors LLC boosted its position in shares of DaVita by 20.8% during the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after acquiring an additional 88 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in DaVita by 19.1% during the first quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock worth $27,403,000 after purchasing an additional 28,739 shares during the last quarter. Truist Financial Corp boosted its holdings in DaVita by 1.9% in the second quarter. Truist Financial Corp now owns 8,646 shares of the company’s stock valued at $1,232,000 after purchasing an additional 163 shares in the last quarter. Ameritas Advisory Services LLC purchased a new position in DaVita in the second quarter valued at approximately $47,000. Finally, KLP Kapitalforvaltning AS raised its holdings in DaVita by 1.1% during the second quarter. KLP Kapitalforvaltning AS now owns 28,614 shares of the company’s stock worth $4,076,000 after purchasing an additional 300 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita News Summary

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: Q1 earnings beat and revenue beat drove the immediate market move; street coverage says the results and management commentary explain the gap‑up. DaVita (NYSE:DVA) Shares Gap Up After Strong Earnings
• Positive Sentiment: News summaries and market stories point to the same drivers (earnings, guidance and volume) as the reason the stock is “rocketing” higher. Why Is DaVita (DVA) Stock Rocketing Higher Today
• Positive Sentiment: Transcript coverage of the Q1 call provides detail on results and FY guidance (management set FY2026 EPS guidance), reinforcing investor confidence in cash flow and earnings trajectory. DaVita (DVA) Q1 2025 Earnings Call Transcript
• Positive Sentiment: Value-oriented outlets (Zacks) are highlighting DVA as a long‑term value idea and discussing the stock in the context of earnings-estimate strength, supporting greater retail/institutional interest. Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term
• Positive Sentiment: Additional Zacks coverage frames DVA as attractive to value investors based on earnings revisions and style scores, which can drive further interest from that investor cohort. Should Value Investors Buy DaVita (DVA) Stock?
• Positive Sentiment: DVA is being featured in thematic/retirement stock lists (Buffett‑style picks), which can lift retail demand and perception of DVA as a long‑term holding. 3 Warren Buffett-Style Stocks for a Golden Retirement
• Neutral Sentiment: Industry/strategic news: an item on Elara Caring and Ares’ backing mentions DaVita in the kidney care ecosystem — relevant to strategic positioning but not an immediate earnings catalyst. Elara Caring Backed By Ares’ Private Equity Group, Kidney Care Provider DaVita
• Neutral Sentiment: Context pieces exploring DVA within the DJIA healthcare space provide useful comparative data but are informational rather than near‑term catalysts. Explore DaVita Within Dow Jones Industrial Average Healthcare Space
• Negative Sentiment: Several analysts are mixed on DVA’s outlook; divergent analyst views could cap upside if estimates or sentiment turn less favorable. Analysts’ Opinions Are Mixed on These Healthcare Stocks: Boston Scientific (BSX) and DaVita (DVA)

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Truist Financial set a $158.00 target price on shares of DaVita in a research report on Thursday. Barclays raised their price objective on DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a report on Tuesday. Weiss Ratings reissued a “hold (c)” rating on shares of DaVita in a report on Monday, December 29th. Zacks Research raised DaVita from a “strong sell” rating to a “hold” rating in a research report on Friday, November 28th. Finally, TD Cowen reaffirmed a “hold” rating on shares of DaVita in a research report on Tuesday. One research analyst has rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $160.50.

DaVita Trading Up 5.2%

DaVita stock opened at $149.42 on Friday. The stock has a 50 day moving average of $114.70 and a two-hundred day moving average of $125.11. DaVita Inc. has a twelve month low of $101.00 and a twelve month high of $178.38. The stock has a market capitalization of $10.55 billion, a price-to-earnings ratio of 15.08, a PEG ratio of 0.50 and a beta of 0.99.

DaVita (NYSE:DVA) last released its quarterly earnings results on Monday, February 2nd. The company reported $3.40 EPS for the quarter, topping the consensus estimate of $3.24 by $0.16. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The business had revenue of $3.62 billion during the quarter, compared to analysts’ expectations of $3.51 billion. During the same quarter in the prior year, the business earned $2.24 earnings per share. The company’s quarterly revenue was up 9.9% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. Equities analysts predict that DaVita Inc. will post 10.76 earnings per share for the current year.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.